Figure 8
Effects of suramin on diabetic neuropathy. Blind analyses of time course of antihyperalgesic effect of suramin (10.0 μg/i.t.) delivered to diabetic neuropathic (ob/ob) and wild-type mice. The experimenter was blind to the treatment in panel A. Each circle/bar represents the mean ± S.E.M. (n=6) and is representative of 2 independent sets of experiments. Statistical analyses were performed by two-way ANOVA followed by a Tukey’s test. The dashed line and number symbol indicate the range of data points where diabetic neuropathic animals differed from the non-diabetic group (P<0.001). (B) Cav3.2 immunoprecipitates from dorsal horns from naïve mice (lane 1), or from diabetic mice treated with either vehicle (lane 2) or suramin (lane 3), were probed for USP5 and analyzed by western blot 90 minutes after i.t. treatment. A blot for actin is shown as control (bottom panel). (C) Cav3.2 immunoprecipitates from dorsal horns from naïve mice (lane 1), or from diabetic mice treated with either vehicle (lane 2) or suramin (lane 3), were probed for Cav3.2 channels, as control. (D) Quantification of USP5 bound to Cav3.2 immunoprecipitates by densitometry. Statistical analysis for mice treated with vehicle vs. mice treated with suramin was done via a Student’s t-test (*P <0.05).